Making Breast Cancer Molecular Subtypes Robust?
A partir d'une base de données portant sur 4 924 patientes atteintes d'un cancer du sein, cette étude évalue l'intérêt d'un outil bioinformatique appelé AIMS ("Absolute Intrinsic Molecular Subtyping") pour identifier un sous-type moléculaire à partir d'un profil d'expression de gènes
Since first being described in 2000 (1), gene expression–based molecular subtypes have become an integral part of both basic and translational breast cancer research. Moreover, incremental research has found the subtypes to provide sufficient information on prognosis and systemic treatment selection to merit inclusion in international guidelines for breast cancer treatment (2). Although various subtype classifiers have been developed (3–6), the different classifiers generally agree on a taxonomy of breast cancer typically encompassing four subtypes (luminal A, luminal B, HER2-enriched, and basal-like)...
Journal of the National Cancer Institute , éditorial en libre accès, 2014